142 related articles for article (PubMed ID: 19864622)
1. Chemical reversal of the RNA gain of function in myotonic dystrophy.
Cooper TA
Proc Natl Acad Sci U S A; 2009 Nov; 106(44):18433-4. PubMed ID: 19864622
[No Abstract] [Full Text] [Related]
2. Pentamidine reverses the splicing defects associated with myotonic dystrophy.
Warf MB; Nakamori M; Matthys CM; Thornton CA; Berglund JA
Proc Natl Acad Sci U S A; 2009 Nov; 106(44):18551-6. PubMed ID: 19822739
[TBL] [Abstract][Full Text] [Related]
3. Systemic Evaluation of Chimeric LNA/2'-O-Methyl Steric Blockers for Myotonic Dystrophy Type 1 Therapy.
Christou M; Wengel J; Sokratous K; Kyriacou K; Nikolaou G; Phylactou LA; Mastroyiannopoulos NP
Nucleic Acid Ther; 2020 Apr; 30(2):80-93. PubMed ID: 31873063
[TBL] [Abstract][Full Text] [Related]
4. Gain of RNA function in pathological cases: Focus on myotonic dystrophy.
Klein AF; Gasnier E; Furling D
Biochimie; 2011 Nov; 93(11):2006-12. PubMed ID: 21763392
[TBL] [Abstract][Full Text] [Related]
5. A reversal of misfortune for myotonic dystrophy?
Cooper TA
N Engl J Med; 2006 Oct; 355(17):1825-7. PubMed ID: 17065646
[No Abstract] [Full Text] [Related]
6. In silico discovery of substituted pyrido[2,3-d]pyrimidines and pentamidine-like compounds with biological activity in myotonic dystrophy models.
González ÀL; Konieczny P; Llamusi B; Delgado-Pinar E; Borrell JI; Teixidó J; García-España E; Pérez-Alonso M; Estrada-Tejedor R; Artero R
PLoS One; 2017; 12(6):e0178931. PubMed ID: 28582438
[TBL] [Abstract][Full Text] [Related]
7. Identification of Plant-derived Alkaloids with Therapeutic Potential for Myotonic Dystrophy Type I.
Herrendorff R; Faleschini MT; Stiefvater A; Erne B; Wiktorowicz T; Kern F; Hamburger M; Potterat O; Kinter J; Sinnreich M
J Biol Chem; 2016 Aug; 291(33):17165-77. PubMed ID: 27298317
[TBL] [Abstract][Full Text] [Related]
8. Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy.
Mankodi A; Takahashi MP; Jiang H; Beck CL; Bowers WJ; Moxley RT; Cannon SC; Thornton CA
Mol Cell; 2002 Jul; 10(1):35-44. PubMed ID: 12150905
[TBL] [Abstract][Full Text] [Related]
9. A flow cytometry-based screen identifies MBNL1 modulators that rescue splicing defects in myotonic dystrophy type I.
Zhang F; Bodycombe NE; Haskell KM; Sun YL; Wang ET; Morris CA; Jones LH; Wood LD; Pletcher MT
Hum Mol Genet; 2017 Aug; 26(16):3056-3068. PubMed ID: 28535287
[TBL] [Abstract][Full Text] [Related]
10. Molecular biology. Neutralizing toxic RNA.
Cooper TA
Science; 2009 Jul; 325(5938):272-3. PubMed ID: 19608901
[No Abstract] [Full Text] [Related]
11. Myotonic dystrophy: clinical and molecular parallels between myotonic dystrophy type 1 and type 2.
Ranum LP; Day JW
Curr Neurol Neurosci Rep; 2002 Sep; 2(5):465-70. PubMed ID: 12169228
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanisms responsible for aberrant splicing of SERCA1 in myotonic dystrophy type 1.
Hino S; Kondo S; Sekiya H; Saito A; Kanemoto S; Murakami T; Chihara K; Aoki Y; Nakamori M; Takahashi MP; Imaizumi K
Hum Mol Genet; 2007 Dec; 16(23):2834-43. PubMed ID: 17728322
[TBL] [Abstract][Full Text] [Related]
13. Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy.
Lin X; Miller JW; Mankodi A; Kanadia RN; Yuan Y; Moxley RT; Swanson MS; Thornton CA
Hum Mol Genet; 2006 Jul; 15(13):2087-97. PubMed ID: 16717059
[TBL] [Abstract][Full Text] [Related]
14. Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA.
Wheeler TM; Sobczak K; Lueck JD; Osborne RJ; Lin X; Dirksen RT; Thornton CA
Science; 2009 Jul; 325(5938):336-9. PubMed ID: 19608921
[TBL] [Abstract][Full Text] [Related]
15. Myotonic dystrophy type 1 (DM1): a triplet repeat expansion disorder.
Kumar A; Agarwal S; Agarwal D; Phadke SR
Gene; 2013 Jun; 522(2):226-30. PubMed ID: 23570879
[TBL] [Abstract][Full Text] [Related]
16. AON-induced splice-switching and DMPK pre-mRNA degradation as potential therapeutic approaches for Myotonic Dystrophy type 1.
Stepniak-Konieczna E; Konieczny P; Cywoniuk P; Dluzewska J; Sobczak K
Nucleic Acids Res; 2020 Mar; 48(5):2531-2543. PubMed ID: 31965181
[TBL] [Abstract][Full Text] [Related]
17. [From gene to disease; altered RNA processing as a cause of myotonic dystrophy type 1].
de Die-Smulders CE; Faber CG; Smeets HJ
Ned Tijdschr Geneeskd; 2005 Sep; 149(37):2043-6. PubMed ID: 16184945
[TBL] [Abstract][Full Text] [Related]
18. A muscleblind knockout model for myotonic dystrophy.
Kanadia RN; Johnstone KA; Mankodi A; Lungu C; Thornton CA; Esson D; Timmers AM; Hauswirth WW; Swanson MS
Science; 2003 Dec; 302(5652):1978-80. PubMed ID: 14671308
[TBL] [Abstract][Full Text] [Related]
19. Nuclear RNA foci in the heart in myotonic dystrophy.
Mankodi A; Lin X; Blaxall BC; Swanson MS; Thornton CA
Circ Res; 2005 Nov; 97(11):1152-5. PubMed ID: 16254211
[TBL] [Abstract][Full Text] [Related]
20. Colocalization of muscleblind with RNA foci is separable from mis-regulation of alternative splicing in myotonic dystrophy.
Ho TH; Savkur RS; Poulos MG; Mancini MA; Swanson MS; Cooper TA
J Cell Sci; 2005 Jul; 118(Pt 13):2923-33. PubMed ID: 15961406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
